PURPOSE: The objective of this study was to clarify whether the alpha-fetoprotein (AFP) reduction rate during preoperative chemotherapy represents a prognostic factor for hepatoblastoma. METHOD: We divided 14 hepatoblastoma patients who underwent preoperative chemotherapy and curative resection into Group A (no recurrence; n = 10) and Group B (recurrence; n = 4). We then compared AFP levels before and after preoperative chemotherapy between groups. RESULT: Mean AFP level after completing the first cycle of chemotherapy was reduced to 7.28 % (range 1.2-36.8 %) in Group A and 17.05 % (range 12.0-20.5 %) in Group B (p < 0.05). Mean AFP after total preoperative chemotherapy was reduced to 1.42 % (range 0.07-8.5 %) in Group A and 7.55 % (range 3.4-12.4 %) in Group B (p < 0.02). Eight patients in whom AFP levels decreased >1 log after the first cycle of preoperative chemotherapy survived without recurrence. CONCLUSION: A large, early decrease in AFP level during preoperative chemotherapy may offer a strong indicator of survival. Patients in whom AFP levels do not decrease easily during preoperative chemotherapy may have increased risk of recurrence and should be followed very closely.
PURPOSE: The objective of this study was to clarify whether the alpha-fetoprotein (AFP) reduction rate during preoperative chemotherapy represents a prognostic factor for hepatoblastoma. METHOD: We divided 14 hepatoblastomapatients who underwent preoperative chemotherapy and curative resection into Group A (no recurrence; n = 10) and Group B (recurrence; n = 4). We then compared AFP levels before and after preoperative chemotherapy between groups. RESULT: Mean AFP level after completing the first cycle of chemotherapy was reduced to 7.28 % (range 1.2-36.8 %) in Group A and 17.05 % (range 12.0-20.5 %) in Group B (p < 0.05). Mean AFP after total preoperative chemotherapy was reduced to 1.42 % (range 0.07-8.5 %) in Group A and 7.55 % (range 3.4-12.4 %) in Group B (p < 0.02). Eight patients in whom AFP levels decreased >1 log after the first cycle of preoperative chemotherapy survived without recurrence. CONCLUSION: A large, early decrease in AFP level during preoperative chemotherapy may offer a strong indicator of survival. Patients in whom AFP levels do not decrease easily during preoperative chemotherapy may have increased risk of recurrence and should be followed very closely.
Authors: D von Schweinitz; D J Byrd; H Hecker; P Weinel; U Bode; D Bürger; R Erttmann; D Harms; H Mildenberger Journal: Eur J Cancer Date: 1997-07 Impact factor: 9.162
Authors: F Sasaki; T Matsunaga; M Iwafuchi; Y Hayashi; H Ohkawa; M Ohira; T Okamatsu; T Sugito; Y Tsuchida; A Toyosaka; N Nagahara; H Nishihira; Y Hata; J Uchino; K Misugi; N Ohnuma Journal: J Pediatr Surg Date: 2002-06 Impact factor: 2.545
Authors: Kyung Nam Koh; Meerim Park; Bo Eun Kim; Keun Wook Bae; Kyung Mo Kim; Ho Joon Im; Jong Jin Seo Journal: Pediatr Blood Cancer Date: 2011-03-02 Impact factor: 3.167
Authors: Maretta De Ioris; Laurence Brugieres; Arthur Zimmermann; Jean Keeling; Penelope Brock; Rudolf Maibach; Jon Pritchard; Liz Shafford; Joszef Zsiros; Piotr Czaudzerna; Giorgio Perilongo Journal: Eur J Cancer Date: 2007-12-31 Impact factor: 9.162
Authors: Jörg Fuchs; Jana Rydzynski; Dietrich Von Schweinitz; Udo Bode; Hartmut Hecker; Peter Weinel; Dietrich Bürger; Dieter Harms; Rudolf Erttmann; Karl Oldhafer; Hermann Mildenberger Journal: Cancer Date: 2002-07-01 Impact factor: 6.860
Authors: Rebecka L Meyers; Jon R Rowland; Mark Krailo; Zhengjia Chen; Howard M Katzenstein; Marcio H Malogolowkin Journal: Pediatr Blood Cancer Date: 2009-12 Impact factor: 3.167
Authors: Harold N Lovvorn; Dan Ayers; Zhiguo Zhao; Melissa Hilmes; Pinki Prasad; Myrick C Shinall; Barry Berch; Wallace W Neblett; James A O'Neill Journal: J Pediatr Surg Date: 2010-01 Impact factor: 2.545
Authors: Paul R Territo; Mary Maluccio; Amanda A Riley; Brian P McCarthy; James Fletcher; Mark Tann; Romil Saxena; Nicholas J Skill Journal: BMC Med Imaging Date: 2015-05-16 Impact factor: 1.930